Swiss dental implant manufacturer contributing industrial biomaterials, 3D printing, and surface engineering expertise to EU research consortia.
Institut Straumann AG is a major Swiss dental implant and oral tissue regeneration company headquartered in Basel. Within H2020, they contribute industrial expertise in biomaterials, 3D-printed implants, and advanced surface treatment technologies for medical applications. Their participation spans additive manufacturing of ceramic-based components, personalized bone regeneration using stem cells and 3D-printed biomaterials, and femtosecond laser surface functionalization — all tied to improving implant performance and manufacturing quality. They bring real-world product development and clinical validation capacity to research consortia.
MAXIBONE focused on personalized maxillofacial bone regeneration with 3D printed biomaterials and mesenchymal stem cells; AMITIE addressed ceramic-based 3D fabrication relevant to implant manufacturing.
AMITIE targeted AM technologies development and ceramic-based 3D fabrication; MAXIBONE applied 3D printing to biomaterials for bone defects.
FemtoSurf explored femtosecond laser surface patterning and multi-beam automated processing for industrial manufacturing applications.
MAXIBONE included randomized clinical trials for vertical bone defect treatment using autologous mesenchymal stem cells.
Straumann's H2020 involvement began in 2017 with broad additive manufacturing and ceramic fabrication (AMITIE), then shifted toward direct biomedical applications — personalized bone regeneration with 3D-printed biomaterials (MAXIBONE, 2018) and precision surface treatment via femtosecond lasers (FemtoSurf, 2019). The trajectory shows a move from general AM technology exploration toward specific clinical and manufacturing applications that feed directly into their implant product pipeline. Their most recent project adds ultra-precise surface engineering, suggesting growing interest in implant surface performance.
Straumann is converging on the intersection of 3D printing, biomaterials, and laser surface treatment — pointing toward next-generation personalized implants with functionally optimized surfaces.
Straumann participates exclusively as a consortium partner, never as coordinator, bringing industrial validation and manufacturing know-how rather than leading research direction. With 41 partners across 12 countries from just 3 projects, they operate in large, multi-national consortia typical of RIA and MSCA-RISE schemes. This suggests they function as an industry end-user that grounds academic research in commercial requirements and clinical reality.
Straumann has built a broad European network of 41 unique partners across 12 countries through only 3 projects, indicating participation in large, diverse consortia. Their Basel base and Swiss identity position them as a neutral, well-connected industry partner across EU research networks.
Straumann is one of the world's largest dental implant manufacturers, which gives their H2020 participation a clear pathway from lab to market that few academic partners can match. They sit at the rare intersection of additive manufacturing, biomaterials science, and clinical deployment — able to validate research outputs against real product and regulatory requirements. For consortium builders, they offer not just technical input but a credible route to commercialization in the dental and maxillofacial space.
